Literature DB >> 10780811

SR 141716A, a CB1 cannabinoid receptor antagonist, potentiates the locomotor stimulant effects of amphetamine and apomorphine.

J M Masserano1, F Karoum, R J Wyatt.   

Abstract

The intraperitoneal (i.p.) injection of apomorphine or d-amphetamine significantly increased locomotor activity in Sprague-Dawley rats. Prior administration of the cannabinoid receptor antagonist, SR 141716A, significantly enhanced the stimulant effect of both d-amphetamine and apomorphine in a dose-dependent manner. Administration of SR 141716A alone had no effect on locomotor activity. These data indicate that endogenous cannabinoids exert an inhibitory action on the increase in locomotor activity produced by amphetamine and apomorphine.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10780811     DOI： 10.1097/00008877-199907000-00010

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN： 0955-8810            Impact factor:   2.293


  9 in total

1.  The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions.

Authors:  Eleni T Tzavara; Richard J Davis; Kenneth W Perry; Xia Li; Craig Salhoff; Frank P Bymaster; Jeffrey M Witkin; George G Nomikos
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

2.  Interactions between dopamine transporter and cannabinoid receptor ligands in rhesus monkeys.

Authors:  David R Schulze; F Ivy Carroll; Lance R McMahon
Journal:  Psychopharmacology (Berl)       Date:  2012-02-29       Impact factor: 4.530

3.  Neural encoding of psychomotor activation in the nucleus accumbens core, but not the shell, requires cannabinoid receptor signaling.

Authors:  Joshua T Morra; Stanley D Glick; Joseph F Cheer
Journal:  J Neurosci       Date:  2010-04-07       Impact factor: 6.167

4.  Rab3B protein is required for long-term depression of hippocampal inhibitory synapses and for normal reversal learning.

Authors:  Theodoros Tsetsenis; Thomas J Younts; Chiayu Q Chiu; Pascal S Kaeser; Pablo E Castillo; Thomas C Südhof
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-15       Impact factor: 11.205

5.  Endocannabinoid modulation of amphetamine sensitization is disrupted in a rodent model of lesion-induced dopamine dysregulation.

Authors:  Sarah A Eisenstein; Philip V Holmes; Andrea G Hohmann
Journal:  Synapse       Date:  2009-11       Impact factor: 2.562

6.  Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats.

Authors:  Maria Sabrina Spano; Liana Fattore; Francesca Cadeddu; Walter Fratta; Paola Fadda
Journal:  Psychopharmacology (Berl)       Date:  2012-08-19       Impact factor: 4.530

7.  Methanandamide attenuates cocaine-induced hyperthermia in rats by a cannabinoid CB1-dopamine D2 receptor mechanism.

Authors:  Bruce A Rasmussen; Esther Kim; Ellen M Unterwald; Scott M Rawls
Journal:  Brain Res       Date:  2009-01-18       Impact factor: 3.252

Review 8.  In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability.

Authors:  Andrea Giuffrida; Lance R McMahon
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-06-10       Impact factor: 3.072

9.  Discriminative stimulus effects in rats of SR-141716 (rimonabant), a cannabinoid CB1 receptor antagonist.

Authors:  Torbjörn U C Järbe; Michele Y Harris; Chen Li; Qian Liu; Alexandros Makriyannis
Journal:  Psychopharmacology (Berl)       Date:  2004-05-27       Impact factor: 4.530
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.